Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Axsome Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders with significant unmet medical need. The company operates within the biotechnology and pharmaceutical industries, targeting neuropsychiatric and neurological conditions that affect large patient populations and are often inadequately treated by existing therapies.
Axsome’s primary revenue drivers are its commercially approved CNS medicines, most notably Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. The company’s strategic positioning is centered on differentiated, mechanistically novel CNS therapies and an integrated model that combines internal research and development with in-house commercial capabilities. Founded in 2012, Axsome evolved from a clinical-stage biotech into a commercial-stage pharmaceutical company following multiple regulatory approvals in the early 2020s.
Business Operations
Axsome operates through a single integrated business model encompassing research and development, regulatory affairs, manufacturing oversight, and commercial sales. Revenue is primarily generated from product sales of Auvelity and Sunosi in the United States, supported by a dedicated neuroscience-focused sales organization. The company also maintains a late-stage and mid-stage development pipeline aimed at expanding both labeled indications and new CNS therapeutic areas.
The company controls proprietary formulation technologies and intellectual property related to its CNS drug candidates. Axsome’s operations include clinical development programs, post-marketing studies, and lifecycle management initiatives. Sunosi is marketed in the U.S. under Axsome’s ownership, while certain ex-U.S. commercialization activities involve regional licensing and distribution partners.
Strategic Position & Investments
Axsome’s strategy emphasizes growth through pipeline advancement, indication expansion of approved products, and selective business development. The company has made significant investments in late-stage clinical trials across indications such as Alzheimer’s disease agitation, migraine, fibromyalgia, and other neuropsychiatric disorders. These programs are intended to leverage Axsome’s CNS expertise and existing commercial infrastructure.
A key strategic transaction was the acquisition of U.S. rights to Sunosi, which expanded Axsome’s commercial portfolio and revenue base. The company continues to invest heavily in research and development, with a focus on novel mechanisms of action and differentiated clinical profiles. Axsome does not operate as a holding company and does not maintain a broad portfolio of unrelated subsidiaries, instead concentrating capital on CNS-focused assets.
Geographic Footprint
Axsome is headquartered in North America, with its corporate headquarters located in New York, United States. The company’s primary commercial operations and revenue generation are currently concentrated in the U.S. market, where its approved products are marketed directly.
Internationally, Axsome has a limited operational footprint, relying on partnerships and licensing arrangements to address markets outside the United States. While the company has global clinical trial activity and intellectual property coverage in multiple regions, its direct commercial presence remains predominantly U.S.-focused.
Leadership & Governance
Axsome is led by a management team with experience across neuroscience drug development, commercialization, and corporate strategy. The leadership emphasizes scientific rigor, disciplined capital allocation, and a long-term vision centered on becoming a leading CNS-focused pharmaceutical company.
Key executives include:
- Herriot Tabuteau, MD – Founder, Chairman, and Chief Executive Officer
- Mark L. Jacobson – Chief Operating Officer
- Seth D. Leonard – Chief Financial Officer
- Thomas A. Cirrito – Chief Commercial Officer
- Adrian Howd, PhD – Chief Scientific Officer
The company is governed by a board of directors that includes industry veterans and financial experts, providing oversight of strategy, risk management, and corporate governance in alignment with public company standards.